CSL Undervalue Gem That Will ReboundCSL LimitedASX_DLY:CSLdanny_peanutsCSL Limited (ASX:CSL) has long been considered one of Australia’s premier healthcare stocks, yet recent trading levels suggest it is undervalued relative to its historical benchmarks. Currently hovering around A$100, CSL is priced well below analyst fair value estimates of A$155, reflecting a discount of roughly 36%. This gap is largely due to FY26 earnings pressure, including US$5 billion in impairments tied to CSL Vifor and restructuring charges that temporarily obscure the strength of its plasma and vaccine businesses. Historically, CSL commanded premium valuation multiples of 28–30x earnings, compared to today’s ~19x. Sector peers average closer to 36x, underscoring the discount. Importantly, CSL’s plasma-derived therapies remain resilient, supported by structural demand drivers such as ageing populations and chronic disease prevalence. The vaccine division also provides defensive earnings streams, though near-term demand fluctuations in the U.S. have weighed on sentiment. The rebound has already begun, with shares climbing 14% from June lows. However, the decisive recovery is expected in FY27, once restructuring charges fade and margins normalize. Key catalysts include successful execution of the CSL Seqirus demerger, stabilization in plasma pricing, and renewed investor rotation into defensive healthcare amid global macro uncertainty. Risks remain: execution missteps in restructuring, prolonged weakness in vaccine demand, or continued capital rotation into growth sectors could delay recovery. Yet, for long-term investors, CSL offers a compelling value play. Its fundamentals—market leadership in plasma therapies, strong R&D pipeline, and defensive healthcare positioning—remain intact. Bottom line: CSL is undervalued today, with the rebound underway but full recovery likely around FY27. Patient investors may find this an attractive entry point into a high-quality healthcare stock poised to regain its premium valuation multiples.